Crispr Therapeutics Ag Stock Today
| CRSP Stock | USD 41.22 0.05 0.12% |
PerformanceWeak
| Odds Of DistressLow
|
Crispr Therapeutics is selling at 41.22 as of the 22nd of March 2025; that is 0.12 percent increase since the beginning of the trading day. The stock's last reported lowest price was 40.41. Crispr Therapeutics has less than a 10 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 90 trading days. Note, on October 5, 2021, Representative Thomas Suozzi of US Congress acquired $50k to $100k worth of Crispr Therapeutics's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 19th of October 2016 | Category Healthcare | Classification Health Care |
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats CRISPR-associated protein 9 platform. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland. The company has 85.77 M outstanding shares of which 20.41 M shares are currently shorted by private and institutional investors with about 8.19 trading days to cover. More on Crispr Therapeutics AG
Moving against Crispr Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Crispr Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsCrispr Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Crispr Therapeutics' financial leverage. It provides some insight into what part of Crispr Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Crispr Therapeutics AG (CRSP) is traded on NASDAQ Exchange in USA. It is located in Baarerstrasse 14, Zug, Switzerland, 6300 and employs 393 people. Crispr Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.53 B. Crispr Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 85.77 M outstanding shares of which 20.41 M shares are currently shorted by private and institutional investors with about 8.19 trading days to cover.
Crispr Therapeutics AG currently holds about 2.07 B in cash with (142.77 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 26.48.
Check Crispr Therapeutics Probability Of Bankruptcy
Ownership AllocationCrispr Therapeutics holds a total of 85.77 Million outstanding shares. The majority of Crispr Therapeutics AG outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Crispr Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Crispr Therapeutics. Please pay attention to any change in the institutional holdings of Crispr Therapeutics AG as this could imply that something significant has changed or is about to change at the company. On October 5, 2021, Representative Thomas Suozzi of US Congress acquired $50k to $100k worth of Crispr Therapeutics's common stock.
Check Crispr Ownership Details
Crispr Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Orbis Allan Gray Ltd | 2024-12-31 | 1.5 M | |
| Ecor1 Capital, Llc | 2024-12-31 | 1.4 M | |
| Baker Bros Advisors Lp | 2024-12-31 | 1.3 M | |
| Bank Of America Corp | 2024-12-31 | 1.2 M | |
| Sr One Capital Management, Lp | 2024-12-31 | 1 M | |
| Geode Capital Management, Llc | 2024-12-31 | 1 M | |
| Dimensional Fund Advisors, Inc. | 2024-12-31 | 947.3 K | |
| Loomis, Sayles & Company Lp | 2024-12-31 | 911 K | |
| Balyasny Asset Management Llc | 2024-12-31 | 893.9 K | |
| Ark Investment Management Llc | 2024-12-31 | 9 M | |
| Capital Research & Mgmt Co - Division 3 | 2024-12-31 | 8.7 M |
Crispr Therapeutics Historical Income Statement
Crispr Stock Against Markets
Crispr Therapeutics Corporate Management
| Samarth Kulkarni | Chief Business Officer | Profile | |
| James JD | General Secretary | Profile | |
| Susan Kim | Vice Relations | Profile | |
| Craig Mello | Scientific Member | Profile | |
| Lawrence Klein | Chief Officer | Profile | |
| Chad Cowan | Scientific Founder | Profile |
Additional Tools for Crispr Stock Analysis
When running Crispr Therapeutics' price analysis, check to measure Crispr Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crispr Therapeutics is operating at the current time. Most of Crispr Therapeutics' value examination focuses on studying past and present price action to predict the probability of Crispr Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crispr Therapeutics' price. Additionally, you may evaluate how the addition of Crispr Therapeutics to your portfolios can decrease your overall portfolio volatility.